Cubist Pharmaceuticals has announced plans to offer convertible senior notes worth up to $800 million, including overallotments. The firm will use proceeds to fund its purchase of Optimer Pharmaceuticals.
Published in Brief:
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore